Medicine and Dentistry
Plasma Exchange
99%
ANCA Associated Vasculitis
54%
Vasculitis
38%
Neutrophil
32%
Randomized Controlled Trial
31%
Meta-Analysis
29%
Glomerulonephritis
28%
Glucocorticoid
26%
Systematic Review
26%
End Stage Renal Disease
21%
Granulomatosis with Polyangiitis
20%
Rapidly Progressive Glomerulonephritis
17%
Kidney Function
16%
Methylprednisolone
14%
Neutrophil Cytoplasmic Antibody
13%
Cyclophosphamide
13%
Cohort Analysis
11%
Anti-Glomerular Basement Membrane Antibody
10%
Plasmapheresis
8%
Autoantibodies
8%
Infection
8%
Drug Megadose
8%
Maintenance Therapy
8%
Proteinase
8%
Clinical Finding
8%
Nephropathy
8%
Retrospective Cohort Study
8%
Pulse Rate
8%
Renal Vasculitis
8%
Lung Cancer
8%
COVID-19
8%
Acute Disseminated Encephalomyelitis
8%
Transverse Myelitis
8%
Azathioprine
8%
Renal Cortical Necrosis
8%
Imlifidase
8%
Nephrology
8%
Renal Failure
8%
Sepsis
8%
Cyclosporine
8%
Goodpasture Syndrome
8%
Erythropoietin
8%
Hazard Ratio
6%
Clinical Trial
6%
Disease
6%
Renal Biopsy
5%
Pulmonary Hemorrhage
5%
Glomerular Filtration Rate
5%
Keyphrases
Plasma Exchange
100%
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
66%
ANCA-associated Vasculitis
34%
Confidence Interval
30%
Meta-analysis
27%
Systematic Meta-analysis
18%
Therapeutic Plasma Exchange
18%
Anti-glomerular Basement Membrane Disease
16%
COVID-19
16%
Cyclophosphamide
15%
Antineutrophil Cytoplasmic Antibody
15%
Methylprednisolone
14%
Non-inferiority
13%
Granulomatosis with Polyangiitis
13%
Randomized Controlled Trial
13%
Associated Vasculitis
12%
End-stage Kidney Disease
12%
Validation Studies
10%
Histological Classification
10%
End-stage Renal Disease
10%
Dosing Regimen
10%
Antibody-associated
10%
Anti-glomerular Basement Membrane Antibody
10%
Rapidly Progressive Glomerulonephritis
9%
Reduced Dose
9%
Kidney Function
9%
Remission Induction
9%
Kidney
9%
Dialysis
9%
Vasculitis
8%
Plasmapheresis
8%
Risk Ratio
8%
Increased Incidence
8%
Sepsis
8%
Renal Vasculitis
8%
Organ Dysfunction
8%
Transverse Myelitis
8%
Initial Maintenance Therapy
8%
Short-term Mortality
8%
Multi-connectivity
8%
Improved Survival
8%
Endopeptidase
8%
National Cohort Study
8%
Avacopan
8%
Acute Disseminated Encephalomyelitis
8%
Imlifidase
8%
Goodpasture's Disease
8%
Severe Acute
8%
Uncommon Presentation
8%
Erythropoietin Deficiency
8%
Pharmacology, Toxicology and Pharmaceutical Science
ANCA Associated Vasculitis
29%
Vasculitis
28%
End Stage Renal Disease
27%
Glucocorticoid
24%
Randomized Controlled Trial
22%
Cohort Study
16%
Glomerulonephritis
16%
Disease
13%
Cyclophosphamide
12%
Cytokine Storm
12%
Infection
11%
Rapidly Progressive Glomerulonephritis
10%
Azathioprine
8%
Remission
8%
Randomized Clinical Trial
8%
Kidney Failure
8%
Sepsis
8%
Avacopan
8%
Kidney Cortex Necrosis
8%
Coronavirinae
8%
Glomerulus Basement Membrane Antibody
8%
Critical Illness
8%
Immunopathogenesis
8%
Proteinase
8%
Erythropoietin
8%
Kidney Disease
8%
Prednisone
6%
Imlifidase
6%
